

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2012

OXIS INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-08092

(Commission File Number)

94-1620407

(I.R.S. Employer Identification No.)

468 N. Camden Dr., 2nd Floor
Beverly Hills, California

(Address of Principal Executive Offices)

90210

(Zip Code)

(310) 860-5184

(Registrant's Telephone Number, Including Area Code)

(Former name, former address, and former fiscal year, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (See General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

OXIS International Reports October Revenues Match Total 3rd Quarter Revenues.

BEVERLY HILLS, Calif., Nov. 6, 2012 (GLOBE NEWSWIRE) -- via PRWEB - OXIS International, Inc., (OXIS) (OXI.PA) today announced revenues for October were in excess of \$105,000. This represents a threefold increase in the average monthly revenue for the 3rd quarter.

David Saloff, OXIS Chairman and CEO stated, "We are extremely pleased with the continued strong revenue growth in October. Both initial and reorders of our products, Prograce (<http://www.prograceyou.com>) and Reverge (<http://www.revergeyou.com>) have increased significantly and exceeded the company's expectations.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and Reactive Oxygen Species (ROS). The company holds the exclusive patent to manufacture EGT, which has received full GRAS (safety) approval. In addition the company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, including EGT(TM) (99% pure L-ergothioneine), known as the intelligent antioxidant.

Contact:

OXIS International
David Saloff
david@oxis.com
424-248-2311